VOR heads into a compressed earnings cycle with short sellers accelerating positions, a freshly reported Q1 beat, and another update due in less than a week.
Short interest has been the defining story of the past fortnight. It climbed 14% in a single week to reach roughly 11.7% of the free float — a level not seen since early April, when availability was far tighter. That 14% weekly rise is the sharpest build in the 30-day window, coming entirely in the last two sessions after short interest had drifted below 10% of the float in late April. Borrow costs have moved in step: the cost to borrow hit 0.99% annualised on May 12, up 24% from the prior week, though still modest in absolute terms. Availability is the one counterpoint — with roughly 158% of short interest still available to borrow, the lending pool is not squeezed. There is plenty of room for shorts to add further without running into a supply wall.
Options sentiment is leaning bullish rather than defensive. The put/call ratio runs at 0.27, barely above its 20-day average of 0.24 and well below the 52-week high of 0.60. That is less than half a standard deviation above the mean — call buyers remain dominant. The ORTEX short score, currently 67.9 out of 100, has been climbing steadily through May, up from 58.8 a week and a half ago. That steady tick higher flags building bearish conviction on a relative basis, even as the lending market remains loose.
The Street picture is broadly constructive but dated. The most recent analyst action on file was in mid-April, when HC Wainwright trimmed its target by $1 to $31 while holding a Buy. Before that, Jefferies initiated with a Buy and a $50 target after the March earnings print, and Wedbush lifted its target from $9 to $15 on the same event. That divergence tells the story: bulls see a significant re-rating opportunity anchored to telitacicept's dual BAFF/APRIL inhibitor profile in autoimmune disease, while sceptics point to a crowded B-cell depletion space and the risk that Chinese trial data does not translate to global approval timelines. The mean price target is $37.50 against a close of $16.47 — implying substantial upside on paper, though the analyst action cut-off was April 15, meaning none of the recent data flow is reflected. Treat those targets as directional guides rather than current marks.
The biggest overhang on the register is RA Capital's exit. The investment manager and 10% owner sold shares on virtually every trading day between April 8 and April 22, offloading roughly 2.2 million shares in total for approximately $35 million. Their reported holding as of April 20 had fallen to 2.57 million shares — less than half what it was in the prior filing. That sustained sell programme coincides almost exactly with the period when short interest dipped from above 10.5% to a trough around 9.5% of the float. As RA's selling eased, short interest resumed its climb — suggesting the two dynamics are at least partially connected, with fresh short positions filling the gap left by the institutional exit.
Today's Q1 print offered the first clean read since the Jefferies initiation: adjusted EPS of -$0.73 beat the -$0.78 estimate. The company also filed its 10-Q and issued a corporate update this morning. The next formal event is scheduled for May 18 — five days away — which the snapshot flags as an earnings call. The prior four earnings reactions have ranged widely: the March 2026 release triggered a 23% one-day gain and a 12% five-day gain, but the November 2025 event produced a -0.5% day-one move followed by a -32% five-day drawdown. That asymmetry — explosive upside on good data, sharp multi-day unwinds on disappointment — is the pattern to watch as the May 18 event approaches with short interest at its highest level in more than a month.
See the live data behind this article on ORTEX.
Open VOR on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
